CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 198 enrolled
Drug / intervention
MenACWY-CRMbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01725217
NCT01725217Phase 3Completed
CompareCT.gov

A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia

Novartis Vaccines·interventional·Posted Nov 12, 2012·Updated Apr 28, 2023

In Brief

A Phase 3 clinical trial evaluating MenACWY-CRM for Meningococcal Disease. Completed, enrolled 198 participants across 4 sites.

Detailed Summary

To evaluate the immune response and safety following a single dose of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy children, adolescents and adults in Russia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningococcal Disease
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 12, 2012
Enrollment StartNov 1, 2012
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.6 years ago

Interventions

MenACWY-CRMbiological

1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection